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Background: An antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used
for clinical purposes. ERCC1 is being explored as a predictive diagnostic biomarker for cisplatin-based
chemotherapy. High ERCC1 expression is linked to drug resistance on cisplatin-based chemotherapy. 8F1 is one of
the most commonly used monoclonal antibodies for evaluating ERCC1 expression levels in lung cancer patient
tissues, but it has been noted that this antibody cross-reacts with an unknown protein.
Results: By using a high density protein microarray chip technology, we discovered that 8F1 not only reacts with
its authentic target, ERCC1, but also cross-reacts with an unrelated nuclear membrane protein, PCYT1A. The
cross-reactivity is due to a common epitope presented on these two unrelated proteins. Similar to the subcellular
localization of ERCC1, IHC tests demonstrated that PCYT1A is localized mainly on nuclear membrane. In this study,
we also discovered that the PCYT1A gene expression level is significantly higher than the ERCC1 gene expression
level in a certain population of lung cancer patient tissue samples. To develop the best monoclonal antibody for
ERCC1 IHC analysis, 18 monoclonal antibodies were generated and 6 of them were screened against our protein
microarray chip. Two clones showed high mono-specificity on the protein microarray chip test and both worked for
the IHC application.
Conclusion: In summary, the 8F1 clone is not suitable for ERCC1 IHC assay due to its cross-reactivity with PCYT1A
protein. Two newly generated monoclonal antibodies, 4F9 and 2E12, demonstrated ultra-specificity against ERCC1
protein and superior performance for IHC analyses.Background
Non-small cell lung cancer (NSCLC) is the most common
form of lung cancer. It accounts for more than 80% of all
lung cancer related deaths [1]. After surgical removal of
NSCLC, cisplatin-based chemotherapy is the first line of
treatment [2]. Cisplatin and its derivatives are mutagenic
chemicals that can induce DNA interstrand or intrastrand
cross links through forming DNA adducts. Tumor cells
damaged by these drugs will trigger cell death [3]. How-
ever, cisplatin-based chemotherapy also causes highly
toxic side effects [4-7]. Recent statistical analysis of clin-
ical data shows that cisplatin-based chemotherapy can
only add an approximately 4–15% survival advantage at* Correspondence: dma@origene.com; whe@origene.com
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reproduction in any medium, provided the orfive years with a subgroup of NSCLC patients exhibiting
no beneficial effects of drug treatment or even worse out-
comes after treatment [8,9]. Thus, it is imperative to use
prognostic or predictive biomarkers to identify patients
who should receive cisplatin-based chemotherapy [10].
Cisplatin or other DNA crosslinkers could cause DNA
damages on either one or two strands of DNA duplex.
In cells, multiple DNA repair pathways are involved in
repairing these damages, including nucleotide excision
repair and interstrand crosslink repair pathway [11].
Therefore, strong endogenous DNA damage repairing
capabilities in tumor cells will compromise the thera-
peutic drug effects of cisplatin [12]. This could be the
major biochemical mechanism that explains different pa-
tient responses towards cisplatin-based treatments [13].
The ERCC1-XPF heterodimeric endonuclease protein. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interstrand crosslink repair pathway. XPF acts as the
catalytic subunit and ERCC1 binds DNA [14]. Quite a
number of clinical studies have already shown a good
correlation between ERCC1 mRNA level and cisplatin
drug resistance [15-17]. This suggests that examining
ERCC1 expression levels might be a good method to
identify patients who are likely to benefit from cisplatin-
based chemotherapy.
To evaluate ERCC1 protein levels in formalin-fixed
paraffin-embedded tissue samples, a high quality mono-
clonal antibody validated for immunohistochemistry is
needed. Currently there are several anti-ERCC1 IHC
antibodies available on the market [18,19]. However, the
published data for them is highly controversial and none
of them is widely accepted as specific for application
in IHC. More than 40 published clinical studies were
conducted using the 8F1 clone making it the most
commonly used anti-ERCC1 diagnostic monoclonal
antibody currently on the market [20-24]. Recently, its
target specificity has been questioned [19,25]. By using
an ERCC1-XPF deficient cell line, Bhagwat et al. dis-
covered that the 8F1 antibody binds to an unknown
cross-reactive protein that migrates at a molecular
weight similar to ERCC1 on SDS-PAGE gels but the
molecular identity for this cross-reactive target was un-
known [19]. In this paper, we describe the development
and application of a high density protein microarray chip.
With this technology, we were not only able to identify
the molecular identity of 8F1 cross-reactive protein, but
also able to use it as a tool to develop two highly specific
monoclonal antibodies for ERCC1 IHC assay.
Methods
The high-throughput production of overexpression
lysates from HEK293T cells transiently transfected with
ORF cDNA expression clones
HEK293T cells from four fully confluent T150 tissue
culture flasks were trypsinized and inoculated into 96
10 cm-tissue culture plates. After culturing for 24 hrs,
cells were transiently transfected with 5ug of TrueORF
cDNA plasmid per plate. After transfection, the cells
were cultured at 37°C for another 48 hrs. Before cell
lysate collection, transfected cells were washed once
with 1xDPBS. Next, 800ul of freshly-prepared native
RIPA lysis buffer (25 mM Tris-HCl pH7.6, 150 mM
NaCl, 1% NP-40, 1 mM EDTA, 1xProtein inhibitor
cocktail mix, 1 mM PMSF and 1 mM Na3VO4) is
added directly to the cells and the plates were incu-
bated on ice for 5 minutes to lyse the cells completely.
The 96 crude cell lysates were transferred to a 96-
deep well plate with 2 ml capacity (Axygen) and spun
at 4000 x rpm to remove insoluble cellular debris. The
clarified supernatants were transferred to a 96-well v-shape plate (BD) and stored at -80C for future protein
microarray printing. The recombinant protein expres-
sion for every overexpression lysate used for micro-
array printing was validated by Western-blot analysis
with the anti-DDK antibody (OriGene, TA50011-100).
Protein microarray printing
All overexpression lysates used for array printing were
obtained from OriGene Technologies Inc. The detailed
protocol for overexpression lysate production is described
as above. Protein microarray printing was performed with
QArray2 array printer (Genetix) with 48 5 um XSMP2
split pins. Grace Biolab Ovid 20X60 mm nitrocellulose
slides were used for printing. The array contains a total of
22,176 spots with 10,464 lysates in duplicates (20,928
spots) and 1248 control spots. The whole slide is divided
into 48 sub-arrays (4X12). For each subarray, 462 samples
were spotted in 22X21 format. As an orientation marker
control, each subarray contains an autofluorescent BSA-
Cy5 and Cy3 mixture spot and a mixed IgG spot (mixture
of human, mouse and rabbit IgGs). There are also add-
itional sub-array controls including a buffer only negative
control, a 1 mg/ml BSA control and a 1 mg/ml HEK293T
lysate control. In addition to above subarray controls, we
also added specific global positive and quantification con-
trols. These controls include serially-diluted IgG mixture
controls placed in sub-arrays C1, C5 and C9. As global
negative control, serially diluted HEK293T lysates were
spotted in subarrays A1, A5 and A9. Since every cDNA
clone used for overexpression lysate production contains a
DDK epitope tag, the recombinant protein expression
level can be detected by using the 4C5 monoclonal anti-
DDK antibody (TA50011-100, OriGene Technologies
Inc.). Because the protein expression level for different
genes varies greatly, two highly purified DDK fusion pro-
teins were used as reference standards for the purpose of
quantification. These two standards are GST and beta-
actin. They are located either in subarray D1, D5 and D9
for GST or subarray B1, B5 and B9 for beta-actin.
Protein microarray immuno-hybridization assay
Before probing, the array chips were hydrated for at least
30 min in 10 ml distilled water followed by a 5 min
equilibration with 5 ml wash buffer (20 mMTris,
150 mMNaCl, 0.05% Tween 20. pH 8.0).
Primary antibody was diluted to 5–10 μg/ml in 1 ml
blocking buffer (StartingBlock T20 (TBS), Thermo) and
added to the array in a ProPlate chamber (Grace-bio).
The arrays were then incubated overnight at 5C with
rocking. After overnight antibody incubation, arrays
were washed briefly with 2 ml of wash buffer, transferred
to Perfect Western 6-sectional short (B130) slide tray
and then washed three times with 5 ml of wash buffer
for 5 minutes each time.
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Labs) was diluted 1:500 in wash buffer, added to the
array slide, and then incubated for another 30 min at RT
with rocking. After incubation, the stained arrays were
washed extensively with distilled water and air-dried.
The arrays were scanned with a Genepix 4100A scanner
and data were analyzed using the appropriate gal file.
The antibodies used for protein microarray chip analysis
include rabbit polyclonal anti-ERCC1 (FL297) (Santa
Cruz), anti-ERCC1 (8F1) (Abcam), and Anti-ERCC1
(4F9 and 2E12) (OriGene Technologies Inc.)Tissue microarray production and Immunohistochemistry
The tissue microarray chip was generated using Sakura’s
Tissue-Tek Quick-Ray system. On one slide, 12 human
normal and 12 human carcinoma tissue samples were
spotted. For immunohistochemical staining of the
tissue-microarray chip and paraffin-embedded tissue
sections, antigen retrieval was carried out in 0.01 M So-
dium Citrate buffer at pH 6 in a pressure cooker for
2 minutes. Samples were blocked with 5% non-fat milk
plus 5% goat serum for 30 min and then incubated with
primary antibody at a 1:150 dilution for 60 min at room
temperature. The primary antibody signal was detected
using polink-2 anti-rabbit or anti-mouse secondary anti-
body for 30 min and DAB substrate for 5 min at room
temperature (GBI Labs). Hematoxylin was used for
counterstaining. The antibodies used for IHC analysis
include anti-PCYT1A (EPR3940) (Epitomics), anti-
ERCC1 (8F1) (Abcam), Anti-ERCC1 (4F9 and 2E12)
(OriGene Technologies Inc.).Quantitative real-time PCR
TissueScan 24 lung cancer panels (HLRT104, OriGene
Technologies) were used to examine ERCC1 and
PCYT1A mRNA expression profiles. The qPCR was per-
formed on ABI 7900HT using the SYBR Green PCR
Master Mix (Applied Biosystems). Primers used for
ERCC1 mRNA detection were HP229725 with 50-
GCTGGCTAAGATGTGTATCCTGG-30 (forward) and
5-ATCAGGAGGTCCGCTGGTTTCT-3 (reverse), for
PCYT1A were HP208235 with 50-GTTCCTTCCAAA
GTGCAGCGCT-30 (forward) and 5-AGGAGTTCCTC
TGCTGGCTTCT-3, for β-actin were HP204660 with
50-CAGCCATGTACGTTGCTATCCAGG-30 (forward)
and 5-AGGTCCAGACGCAGGATGGCATG-3 (OriGene
Technologies Inc.). Relative quantification of ERCC1 and
PCYT1A expression were measured by normalization
against β-actin using the ΔCT method. The PCR effi-
ciency values of E(ERCC1), E(PCYT1A) and E(β-actin)
were determined using the copy number standards,
HK202848, HK209617 and HK200550 respectively (Ori-
Gene Technologies Inc.).Immunoblotting and recombinant protein affinity
purification
For immunoblotting, overexpression lysates (OriGene
Technologies Inc.) or purified proteins were mixed with
4XSDS sample buffer (Invitrogen), boiled for 5 minutes
before loading on SDS-PAGE for fractionation. After
separation on SDS-PAGE gel, they were electro-blotted
on a nitrocellulose membrane. Anti-DDK (OriGene
Technologies Inc.), anti-ERCC1 (8F1) (Abcam) or anti-
ERCC1 (4F9 or 2E12) (OriGene Technologies Inc.) was
used for immunoblotting.
For affinity purification of recombinant protein,
HEK293T cells were first transiently transfected with an
OriGene TrueORF cDNA clone (OriGene Technologies
Inc.). After 48 hrs, transfected cells were collected and
lysed with RIPA buffer (25 mM Tris-HCl pH7.6,
150 mM NaCl, 1% NP-40, 1xProtein inhibitor cocktail
mix, 1 mM PMSF, 1 mM EDTA and 1 mM Na3VO4)
and the cellular debris were removed by high speed cen-
trifugation. For affinity purification, anti-DDK agarose
beads were first balanced with RIPA buffer, and then
added to pre-cleared overexpression lysates for overnight
incubation. After incubation, the beads were extensively
washed and purified proteins were eluted from the beads
using a 0.1 M Glycine-HCl (pH2.3) solution.
Results
Development of a high density overexpression lysate
protein microarray chip for the evaluation of antibody
specificity
Figure 1 is the basic production scheme for this protein
microarray chip. In summary, 10,464 unique overexpres-
sion lysates were spotted in duplicate on a single nitro-
cellulose coated glass slide. The detailed description of
protein microarray production and calibration is pro-
vided in the materials and methods section. To ensure
that the immunoassay experiments with these chips are
reproducible and interpretable, multiple internal con-
trols were spotted on the chip (Figure 2A).
Using a high density protein microarray chip to evaluate
the target specificity of anti-ERCC1 monoclonal
antibodies
To evaluate the 8F1 target specificity, this antibody was
incubated at 5ug/ml concentration with the protein
microarray chip. As suspected from Bhagwat et al, 8F1
not only reacts with its authentic target ERCC1 protein,
but also binds strongly with an un-related nuclear pro-
tein, PCYT1A (see subarray 6B in Figure 2A). PCYT1A
is an important enzyme in regulating phosphatidylcho-
line biosynthesis and nuclear membrane expansion [26].
The functionality of this protein is actively regulated by
a rapid translocation between a cytoplasmic soluble form
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Figure 1 The production scheme for the protein microarray chip. All the overexpression lysates were produced using OriGene’s TrueORF
cDNA clone collection. On a single nitrocellulose slide, over 22,000 protein samples were spotted. These include 10,464 unique gene
overexpression lysates printed in duplicate and large selections of positive and negative controls. Since all the expression clones contain a
universal Myc and DDK fusion tag, the target gene expression level can be examined by using an Anti-DDK antibody (1:500 dilution of OriGene







































Figure 2 The identification of the 8F1 cross-reactive protein with protein microarray chip and Western blot confirmation. A. Protein
microarray hybridization with 8F1. The OriGene overexpression protein microarray chip was immunostained with the most commonly used 8F1
monoclonal anti-ERCC1 antibody. The positive reactive proteins are highlighted with red arrows. These data show that 8F1 recognizes not only
its specific target (two ERCC1 transcript variants), but also another unrelated nuclear membrane protein PCYT1A. A number of internal controls
were also labeled on the panel. B. Western Blot analysis. Seven OriGene VERIFY™ overexpression lysate antigen standards (Lane 1 to 7) were
fractionated on SDS-PAGE, and then immunoblotted with 8F1 (Upper panel). The recombinant protein expression levels within the lysates were
analyzed with anti-DDK antibody (Lower panel). Lanes 1 to 7 are loaded with samples for ERCC1 (NM_202001), ERCC1 (NM_001983), ERCC2
(NM_000400), ERCC3 (NM_000122), ERCC4 (NM_005236), ERCC5 (NM_000123) and PCYT1A (NM_005017).
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relation between PCYT1A expression levels and patient
response to cisplatin-based chemotherapy.
Rabbit polyclonal antibody FL297 is another com-
monly used anti-ERCC1 IHC antibody. Studies from a
number of groups suggested that the target specificity
for FL297 could be considerably better than 8F1 under
their IHC experimental conditions [18,19,28,29]. To
evaluate the specificity of this antibody, protein micro-
array chip hybridization and Western blot confirmation
were performed. In comparison with the 8F1 monoclo-
nal antibody, this rabbit antibody exhibits much broader
cross-reactivity and higher background signals across the
entire chip (see Additional file 1: Figure S1). On subar-
rays 2C and 2D, FL297 reacts with two ERCC1 recom-
binant protein isoforms encoded by two different
transcript variants. However, it also shows strong cross-
reactivity with two unrelated protein targets, PDK1 and
FERMT3. This cross-reactivity was confirmed by WB
analyses of PDK1 and FERMT3 overexpression lysates
(Additional file 2: Figure S2). PDK1 is a central mediator
of cellular signaling between PI-3 kinase and various
intracellular serine/threonine kinases, including pro-
tein kinase B, p70 ribosomal S6 kinase, serum and
glucocorticoid-inducible kinase, and protein kinase C.
FERMT3 is a focal adhesion molecule implicated in in-
tegrin activation. So far there are no published results
linking the protein or gene expression levels of either
PDK1 or FERMT3 with the patient response to cisplatin-
based chemotherapy. In terms of subcellular localization,
neither of these two cross-reactive proteins is located in
the nuclear region. These data are well correlated with
previous observations that IHC immunostaining with
FL297 shows some cytoplasmic staining [18].Immunoassay analysis to confirm the protein microarray
hybridization data with cross-reactive targets
To further confirm the protein microarray data, Western
blot analyses were performed with OriGene’s VERIFY™
overexpression lysates. As negative controls, we included
4 different ERCC family members on the same WB to
confirm the antibody specificity. Figure 2B is the repre-
sentative WB data with clone 8F1 (Figure 2B upper
panel). From this data, it is clear that 8F1 not only
recognizes ERCC1 protein, but also PCYT1A strongly.
No cross-reactivity was observed with other ERCC fam-
ily members. The WB membrane was also re-blotted
with anti-DDK antibody to confirm the expression of
the different recombinant proteins for each of the input
lysates (Figure 2B lower panel).
One of the intrinsic questions with this WB data is
that the SDS-PAGE gel migration location of ERCC1
and PCYT1A molecule is barely distinguishable, eventhough PCYT1A is 10 kDa larger than ERCC1. This ob-
servation is well correlated with the previous publication
from Bhagwat NR, et al [19]. By using an ERCC1
depleted cell line, they detected an unidentified 8F1
cross-reactive nuclear protein with similar molecular
weight. Although this data could be explained as the
abnormal SDS-PAGE migration pattern of PCYT1A
protein itself, it is also possible that the observed WB
signal could be due to up-regulated endogenous ERCC1
protein upon transient overexpression of PCYT1A. To
distinguish between these possibilities, we performed
immunoassays with highly purified recombinant proteins
instead of crude overexpression cell lysates. The SDS-
PAGE gel electrophoresis data in Figure 3A shows that
the highly purified ERCC1 and PCYT1A recombinant
proteins exhibit very similar migration patterns. In order
to compare the immunoreactive signal strength between
8F1 and these two highly purified recombinant proteins,
equivalent amounts of protein were loaded on each lane
for WB analysis. Interestingly, our data shows that WB
band intensity is also nearly identical (Figure 3B). These
data demonstrate that 8F1indeed binds PCYT1A protein
with similar affinity to its authentic target, ERCC1
protein.
One possible explanation for this antibody cross-
reactivity could be high sequence homology between its
authentic target and the cross-reactive protein. To under-
stand whether there is any amino acid sequence hom-
ology, we carried out an amino acid sequence alignment
of ERCC1 and PCYT1A. No significant homology was
detected (data not shown). However, it is possible that
the epitope recognized by 8F1 is a discontinuous epitope
and that a similar conformational epitope exists on
PCYT1A because 8F1 was generated by using full length
human recombinant ERCC1 protein as immunogen.
Monoclonal antibodies are produced by hybridoma
cell lines, which are generated by the fusion between an
antibody secreting B cell and a myeloma cell. Whether
multiple B cells can fuse with one myeloma cell and pro-
duce different antibodies from a single hybridoma clone
is still under-debate [30,31]. If this does occur, it raises
the possibility that multiple antibodies can be secreted
from one hybridoma. Alternatively, hybridoma clone im-
purity could also attribute to the contamination of 8F1
antibody preparation. To evaluate contamination as the
source of cross-reactivity, a set of immunogen absorp-
tion experiments were performed. As shown in
Figure 3C, the immunoreactivities toward both PCYT1A
and ERCC1 were ablated effectively after the pre-
absorption with purified PCYT1A protein. However, no
signal depletion was observed under the control experi-
mental condition that used purified BSA protein as the
negative control (data not shown). These data clearly
demonstrate that a single 8F1 IgG molecule exhibits bi-






























Figure 3 8F1 immunoblot analyses with purified proteins and antigen absorption test. A. Coomassie staining of purified ERCC1 and
PCYT1A proteins. 1ug of affinity purified recombinant ERCC1 and PCYT1A proteins were fractionated on the SDS-PAGE gel and then
commassie-stained. B. Immunoblot analysis with 8F1 anti-ERCC1 mAb.0.5ug of purified ERCC1 (Lane 2) and PCYT1A (Lane 4) were loaded on an
SDS-PAGE gel and then immunobloted with 8F1 antibody. Empty vector transfected HEK293T cell lysates (Lanes 1 and 3) were used as a negative
control. C. Antigen absorption test. Overexpression lysates for PCYT1A (Lane1), ERCC1 (Lane 3), and empty vector transfected control (Lanes 2
and 4) were fractionated on SDS-PAGE, and then immunoblotted with 8F1 (upper panel) or 8F1 pre-depleted with purified PCYT1A protein
(lower panels).
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PCYT1A protein.
The immunohistochemical staining of NSCLC tissue
sections with anti-ERCC1 and anti-PCYT1A monoclonal
antibodies
ERCC1 protein is proposed as an important biomarker
for clinicians to predict whether a certain patient popu-
lation with non-small cell lung carcinoma (NSCLC) will
respond to cisplatin chemotherapy [9]. For pathological
evaluation via the application of IHC analysis, nuclear
immunostaining intensity is the critical measurement.
The 8F1 cross-reactive protein, PCYT1A, is a nu-
clear membrane protein. However, previous immuno-
cytochemistry studies indicated that the subcellular
localization for PCYT1A is dynamically regulated
under different physiological conditions and it canPCYT1A
Figure 4 The immunohistochemistry staining on NSCLC tissue section
monoclonal anti-ERCC1 antibody. Pathologist-validated NSCLC FFPE tissu
re-hydrated before IHC testing. The primary antibodies (Left: rabbit anti-PCY
were diluted at 1:150 dilution with blocking buffer.switch between an inactive soluble or cytoplasmic form to
an active, membrane-bound species within the nucleus
[27]. There are very few reports of immunohistochemistry
analysis of PCYT1A protein in different tissues and those
data are highly controversial [32].
To check the subcellular distribution pattern for
PCYT1A protein in NSCLC tissue samples, IHC experi-
ments were performed in parallel using either the rabbit
monoclonal anti-PCYT1A or mouse 8F1 anti-ERCC1
antibody. Representative IHC images are in Figure 4.
These data clearly show that PCYT1A IHC staining is
localized primarily in the nucleus compartment and that
the staining pattern is very similar to that seen with the
anti-ERCC1 8F1 clone.
To further survey the PCYT1A protein tissue expres-
sion profile, IHC analyses were performed on a tissue
microarray slide containing 12 normal human tissue8F1
s with rabbit monoclonal anti-PCYT1A antibody or 8F1 mouse
e blocks were cut into thin sections, and then further deparaffinized,
T1A mAb, Right: 8F1 anti-ERCC1 mAb) used for these experiments
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ples. The IHC data with positive staining are shown in
Additional file 3: Figures S3A and Additional file 4: Figure
S3B. In summary, PCYT1A is primarily localized within
nucleus under our current experimental conditions.
Comparison of ERCC1 and PCYT1A mRNA transcript levels
by qPCR analysis on lung cancer patient tissue samples
Western blot analysis showed that there is no significant
difference in terms of the binding efficiency for 8F1 to
ERCC1 or to PCYT1A and our IHC data also demon-
strated that ERCC1 and PCYT1A protein are colocalized
within the nucleus compartment in NSCLC patient tis-
sue samples. To facilitate our understanding of how
much 8F1 nuclear immunostaining signal might be coming
from 8F1-PCYT1A interaction, we wanted to compare the
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Figure 5 qPCR analysis of mRNA expression profile for ERCC1 and PC
The experimental data using OriGene’s ERCC1 and PCYT1A qPCR standards
B. qPCR lung cancer tissue expression analysis. qPCRdata on OriGene’s Tiss
grouped based on cancer patient stages.ERCC1 in lung cancer patients. However, the binding
efficiency difference between each antibody-antigen pair
would make it exceedingly difficult to estimate the
endogenous protein expression level based on immuno-
assay data. Thus, we used a qPCR method to compare
the endogenous expression at the mRNA level.
Quantitative real-time PCR can provide direct mea-
surements of mRNAs level for different genes in the
same tumor tissue sample. To ensure PCR amplifica-
tion occurs at the same efficiency and to obtain an
absolute mRNA copy number in the tissue mRNA
samples, OriGene’s gene-specific qPCR copy number
standards were serial-diluted and used for CT value
measurement. The final data are summarized and
plotted in Figure 5A. Our data show that the gene-
specific probes chosen for ERCC1 and PCYT1A exhibit
similar amplification efficiencies with their target genes. + 31.002
28
00001000000
Stage II Stage III
12 13 14 15 16 17 18 19 20 21 22 23 24
YT1A genes on 24 lung cancer patient tissues. A. qPCR standard.
. A formula for copy number calculation is shown on the chart.
ueScan lung cancer cDNA array panel (HLRT104). The data were
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based on the standard curves.
To examine the gene expression levels for ERCC1 and
PCYT1A in different cancer patient tissue samples, we
performed qPCR analysis on OriGene’s lung cancer
qPCR TissueScan cDNA array panel, which contains
cDNA from 24 lung cancer patient tissues. The final
result is presented in Figure 5B. The majority of samples
show that the mRNA expression level for ERCC1 is
higher than that of PCYT1A. However, four lung cancer
patient samples exhibited higher PCYT1A mRNA ex-
pression levels than ERCC1 mRNA expression. This
clearly demonstrates that in a certain lung cancer patient
population, a significant amount of 8F1 immunoreactive
signal could come from the 8F1-PCYT1A interaction
and argues against the use of the 8F1 clone for ERCC1
IHC diagnostic assays. It also highlights the need to
generate a highly mono-specific monoclonal antibody
for ERCC1 clinical applications.
Using a high density protein microarray chip to develop
the most specific monoclonal anti-ERCC1 antibody for
diagnostic IHC testing
To obtain highly mono-specific antibodies for ERCC1
IHC application, we used full-length human recombin-
ant ERCC1 protein as the immunogen. This protein was
purified from HEK293T cells that were transiently trans-
fected with an ERCC1 cDNA clone (see Additional file
5: Figure S4 for coomassie staining of purified ERCC1).
To ensure that we would generate the best IHC mAbs
against ERCC1, we performed more than 8 fusions and
got 18 positively validated hybridoma clones. All 18
mAbs were evaluated by Western-blotting the ERCC1
overexpression lysate and whole cell lysates of endogen-
ous protein from 9 different cell lines. Our initial data
showed that all 18 mAbs worked well with the ERCC1
overexpression lysate and four of them detected en-
dogenous ERCC1 protein by Western blot with the cell
line lysates (Additional file 6: Figures S5 and Additional
file 7: Figure S6 show Western blot data for clones 4F9
and 2E12).
To identify the most specific anti-ERCC1 monoclonal
antibodies for IHC application, we picked six different
mAbs for protein microarray hybridization experiments.
Although all of them can detect ERCC1 on the protein
microarray chip, only three of them exhibited specificity
without any cross-reactivity (Figure 6A and Additional
file 8: Figure S7). Figure 6A is the representative protein
microarray hybridization data on one of the clones, 4F9.
The data were further confirmed by WB analysis
(Figure 6B). To evaluate their performance in the IHC
immunostaining application, two of the most specific
clones, 4F9 and 2E12, were used on NSCLC FFPE tissue
sections. Figure 7 shows that these two clones exhibitvery distinct nuclear staining. Further experimental evi-
dence demonstrated that the immunoassay performance
for 2E12 clone is actually even better than 4F9 clone and
exhibits much stronger binding affinity towards ERCC1
protein in native cell lines (Figure S6). In summary, we
have successfully developed two highly specific anti-
ERCC1 monoclonal antibodies for IHC pathological
application.
Discussion
Immunohistochemistry (IHC) is a widely used antibody-
based assay for pathologists to semi-quantitatively meas-
ure tumor biomarker expression. Due to the nature of
IHC assay itself, the quality of IHC data depends heavily
on the quality of the antibody. Therefore, to develop a
validated IHC assay for clinical usage, the first step is to
identify antibodies with the highest specificity on their
authentic targets. Clinical studies have shown that the
level of ERCC1 gene expression in cancer patients is cor-
related to drug resistance of cisplatin-based chemother-
apy [33]. Currently, there is no clinically approved
ERCC1 IHC diagnostic assay available, likely due to the
lack of a high quality anti-ERCC1 monoclonal antibody.
Studies from a number of labs have shown that the 8F1
clone gives the best performance on NSCLC tissue in
IHC assays [18,34]. However, Bhagwat, et al. claimed that
8F1 is not mono-specific [19]. By using an ERCC1 gene-
ablated fibroblast cell line, they found that 8F1 can still
binds to a specious immunoreactive band exhibiting a
similar SDS-PAGE migration pattern as ERCC1. Interest-
ingly, immunofluorescence experiments showed that this
spurious 8F1 binding protein also localized in the nu-
cleus. In this study, we have successfully identified
PCYT1A, a nuclear membrane protein, as the 8F1 cross-
reactive protein. We also found that PCYT1A exhibits
similar biochemical and immunohistochemical proper-
ties as the spurious target discovered by Bhagwat et al.
For example, PCYT1A shows a similar migration pattern
as ERCC1 protein on SDS-PAGE gel even though it has a
predicted molecular weight 10 kDa greater than ERCC1,
and PCYT1A is localized exclusively in the nucleus by
IHC. Alignment of the primary protein sequences
showed no significant sequence homology between
ERCC1 and PCYT1A, thus, it is likely that 8F1 recog-
nizes a common conformational epitope on these two
proteins. Although the 8F1 antibody binds equally well
with ERCC1 or PCYT1A protein, there is no evidence
that these two proteins share any functional relationship
in development of drug resistance of cisplatin-based
chemotherapy. Obviously, if a pathologist chose to use
8F1 antibody for ERCC1 protein expression evaluation, a
potentially confounded result would be generated.
It is without question that high specificity is the pre-
requisite for any antibody to be used for clinical
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Figure 6 To develop the most highly specific anti-ERCC1 monoclonal antibody with a protein microarray chip. A. Specificity evaluation
with a protein microarray chip. The overexpression protein microarray chip was immunostained with the 4F9 clone. This data shows that 4F9 is
highly specific to ERCC1 (indicated with red arrows). No cross-reactivity was observed with any other test protein. B. Western Blot confirmation
analysis. Seven OriGene VERIFYTM overexpression lysate antigen standards (Lane 1 to 7) were fractionated on SDS-PAGE, and then immunoblotted
with 4F9. The recombinant protein expression levels for the each of the different protein overexpression lysates were confirmed with the
anti-DDK antibody (Figure 2B). Lanes 1 to 7 are loaded with samples for ERCC1 (NM_202001), ERCC1 (NM_001983), ERCC2 (NM_000400), ERCC3
(NM_000122), ERCC4 (NM_005236), ERCC5 (NM_000123) and PCYT1A (NM_005017).
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monoclonal antibody might not be mono-specific.
Therefore, it is very critical to evaluate the specificity for
every antibody to be utilized clinically. Scientists have
spent years working to develop technologies to evaluate
antibody specificity but we still do not have a platform
that can address this question universally. At this stage,
Western blot is the most commonly used approach to
evaluate antibody specificity [35]. A single WB band at
the right molecular weight is considered the primary cri-
teria for antibody specificity. However, there are still a
number of intrinsic issues that could lead to the wrong
conclusion regarding antibody specificity. For example,
the SDS-PAGE gel migration patterns for certain pro-
teins, especially membrane proteins, do not always align4F9
Figure 7 The immunohistochemistry staining on NSCLC tissue section
antibodies. Pathologically-validated NSCLC FFPE tissue sections were used
antibody dilution factor (1:150) and incubation condition. The IHC data forwell with their theoretically predicted molecular weights
[36]. In another case, if a cross-reactive protein co-
migrates with the authentic target on SDS-PAGE gel, it
will be extremely difficult for us to distinguish them. For
some target genes, the expression may be regulated in a
highly temporal and spatial manner making an assess-
ment by W. blotting uninformative from a clinical per-
spective [37,38]. Therefore, it is difficult to find a single
type of cell line or tissue to evaluate antibody specificity
in an unbiased way. The ultimate goal for antibody spe-
cificity testing is to evaluate whether a particular anti-
body will only bind to its authentic target, but not with
other proteins within the human genome. Therefore,
under the dream scenario, this antibody should be tested
against every single human protein in the genome,2E12
s with two newly developed mouse monoclonal anti-ERCC1
for IHC tests. All the IHC experiments were performed under the same
two mouse monoclonal antibodies (Left: 4F9; Right: 2E12).
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protein microarray chip with its high throughput cap-
acity provides a perfect technology platform. Since each
protein target is spotted and annotated at a specific site
on the chip, tens of thousands of target specific
immuno-reactions can be performed simultaneously. In
this study, we utilized OriGene VERIFY™ overexpression
lysates collection for protein microarray chip generation.
One of the major concerns is whether the endogenous
protein expression within HEK293T cells will potentially
create a background signal that masks the specific target
on each crude lysate spot. According to our data, we
found that the protein expression level for most of the
exogenously expressed recombinant proteins is hun-
dreds or even thousands times higher than their en-
dogenous counterparts (data not shown). This is partly
due to the utilization of a strong CMV promoter to
boost the transcription level and to the presence of large
T antigen within HEK293T that permits amplification of
the transfected plasmids containing an SV40 replication
origin. We also have data showing that a large number
of membrane proteins, which are nearly impossible to
purify, can be produced in large quantities in HEK293T
cells and extracted efficiently under our lysis buffer con-
ditions (data not shown). In this study, our experimental
data clearly demonstrate that this chip is a perfect tool
for antibody specificity testing. We believe that every po-
tential diagnostic or therapeutic antibody should be eval-
uated on a genome-wide coverage protein microarray
chip for mono-specificity before application in a clinical
setting.
Conclusion
In conclusion, we developed a high density protein
microarray chip for antibody specificity evaluation. With
this technology, we screened a number of commonly
used anti-ERCC1 antibodies and discovered that 8F1,
the most cited monoclonal antibody in clinical studies, is
not specific. This antibody not only reacts with its au-
thentic target, but also cross-reacts with PCYT1A, a nu-
clear membrane protein with no clinical implication on
Cisplatin drug resistance. In the meantime, we also gen-
erated two IHC mouse monoclonal antibodies with ex-
clusive target specificity, which were proofed by the high
density protein microarray chip platform. Antibodies
from these two clones, 2E12 and 4F9, also demonstrated
superior performance on IHC application with NSCLC
patient FFPE tissue sections.
Additional files
Additional file 1: Figure S1. The identification of polyclonal FL297
cross-reactive proteins with protein microarray chip. The high density
protein microarray chip was immunostained with rabbit polyclonal anti-ERCC1 antibody FL297. The positive reactive proteins are pointed with
red arrows. This data shows FL297 reacts strongly not only with its
specific target (two ERCC1 transcript variants), but also two unrelated
cytosolic proteins (FERMT3 and PDPK1).
Additional file 2: Figure S2. Western blot analysis of FL297 with
different overexpression lysates. The reactive lysates identified on Figure
S1 were further analyzed by using rabbit polyclonal antibody FL297. Each
lane was labeled accordingly.
Additional file 3: Figure S3A. The immunohistochemistry staining on
different normal human tissue sections with rabbit monoclonal anti-
PCYT1A antibody. TMAs with 12 different tissue sections were
immunostained by using rabbit monoclonal anti-PCYT1A antibody at
1:150 dilution. The representative IHC images for tissues with positive
staining are shown here.
Additional file 4: Figure S3B. The immunohistochemistry staining on
different human carcinoma tissue sections with rabbit monoclonal anti-
PCYT1A antibody. TMAs with 12 different carcinoma tissue sections were
immunostained by using rabbit monoclonal anti-PCYT1A antibody at
1:150 dilution. The representative IHC images for tissues with positive
staining are shown here.
Additional file 5: Figure S4. Highly purified full length human
recombinant ERCC1 protein used as immunogen. HEK293T cells were
transiently transfected by using OriGene ERCC1 TrueORF gold cDNA
clone. After transfection, the cells were culture at 37C for another 48 hrs
before collection and lysis. The overexpressed recombinant ERCC1
protein was further purified by using anti-DDK affinity column. 0.5ug of
purified ERCC1 was loaded for SDS-PAGE analysis.
Additional file 6: Figure S5. Immunoblot analysis with 4F9 anti-ERCC1
monoclonal antibody. A. ERCC1 VERIFYTM overexpression HEK293T cell
lysate (Right lane) and empty vector negative HEK293T cell lysates (Left
lane) were fractionated on SDS-PAGE and then immuoblotted with 4F9.
B. Cell lysates prepared from 9 different cell lines were fractionated on
SDS-PAGE gel and then immunoblotted with 4F9.
Additional file 7: Figure S6. Immunoblot analysis with 2E12 anti-ERCC1
monoclonal antibody. A. ERCC1 VERIFYTM overexpression HEK293T cell
lysate (Right lane) and empty vector negative HEK293T cell lysates (Left
lane) were fractionated on SDS-PAGE and then immuoblotted with 2E12.
B. Cell lysates prepared from 9 different cell lines were fractionated on
SDS-PAGE gel and then immunoblotted with 2E12.
Additional file 8: Figure S7. Protein microarray chip hybridization with
two newly developed mouse monoclonal anti-ERCC1 antibodies. The
positive reactive proteins are pointed with red arrows. These data show
that both clones are highly specific. A. Protein microarray chip
hybridization data for clone 3 F6. B. Protein microarray chip hybridization
data for clone 2E12.
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